Filing Flows › Cumberland Pharmaceuticals (CPIX) › Q4 2024
Cumberland Pharmaceuticals (CPIX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 7, 2025
Cumberland Pharmaceuticals (CPIX) reported revenue of $10.4M for the fourth quarter 2024 (Q4 2024), +12% from a year earlier and +15% from the quarter before. Operating margin was -17.7%, net loss $1.9M (18.2% of revenue).
Cumberland Pharmaceuticals, Q4 2024: revenue $10.4M (+12% year over year), operating margin -17.7%, net loss $1.9M, operating cash flow $1.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.4M | +15% | +12% |
| Operating profit | −$1.8M | — | — |
| Net earnings | −$1.9M | — | — |
| Operating cash flow | $1.9M | +301% | +83% |
| Free cash flow | $1.9M | +313% | +92% |
What changed
Revenue was $10.4M in Q4 2024, up 12% year over year and up 15% from the previous quarter.
Operating costs exceeded revenue by $1.8M, an operating margin of -17.7%. Total costs fell 21% while revenue rose 12%. The fastest-growing cost line was Cost of revenue (+29%). The quarter ended with a net loss of $1.9M, wider than the previous quarter's $1.5M loss.
Operating cash flow was $1.9M (up 83% year over year). Non-cash charges added back $1.5M of depreciation and amortization and $75K of share-based compensation. Working capital and other items added $2.2M. Capital expenditures of $2K left free cash flow of $1.9M.
Questions
What was Cumberland Pharmaceuticals' revenue in the fourth quarter 2024?
Cumberland Pharmaceuticals (CPIX) reported revenue of $10.4M for the fourth quarter 2024 (Q4 2024), +12% from a year earlier and +15% from the quarter before.
Was Cumberland Pharmaceuticals profitable in the fourth quarter 2024?
Operating loss was $1.8M (-17.7% of revenue) and net loss $1.9M.